Maha Hussain
Medical Oncology · Ann Arbor, MINPI 1245316199
Payments from drug & device makers
Across 150 payments — averaging $20,270 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2.1M
- Medivation LLC.$288K
- Pfizer$205K
- Bayer$177K
- Genentech, Inc.$141K
- Epizyme, Inc.$35K
- plus $108K from 20 others
Across 44 payments — averaging $928.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$28K
- Astellas Pharma Global Development$8K
- Novartis$4K
- F. Hoffmann-la Roche AG$237
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $2,085,258 |
| Medivation LLC. | 16 | $288,035 |
| Pfizer | 14 | $205,437 |
| Bayer | 31 | $176,980 |
| Genentech, Inc. | 6 | $141,479 |
| Epizyme, Inc. | 1 | $35,000 |
| Astrazeneca UK Limited | 8 | $22,291 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17,500 |
| F. Hoffmann-la Roche AG | 5 | $13,777 |
| Merck | 4 | $9,796 |
| AbbVie | 12 | $8,325 |
| Astellas Pharma US Inc | 2 | $7,393 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,520 |
| Novartis | 3 | $5,469 |
| Janssen Scientific Affairs, LLC | 3 | $3,243 |
| GSK | 2 | $3,200 |
| Advanced Accelerator Applications | 1 | $3,000 |
| Daiichi Sankyo Inc. | 3 | $2,020 |
| Janssen Global Services, LLC | 1 | $1,925 |
| Sanofi | 2 | $1,701 |
| Johnson & Johnson | 3 | $1,667 |
| Progenics Pharmaceuticals, Inc. | 1 | $198 |
| Blue Earth Diagnostics | 1 | $155 |
| Sumitomo Pharma America, Inc. | 1 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Roche Products Limited | 1 | $13 |
How this compares
$3,040,498 in reported general payments places this provider in the 85th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Ann Arbor
- Moshe TalpazAnn Arbor$13.7M
- Zachery ReichertAnn Arbor$10.6M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Vaibhav SahaiAnn Arbor$5.4M
- Francis WordenAnn Arbor$4.2M
- Harry ErbaAnn Arbor$4.1M
- Angel QinAnn Arbor$3.3M
- Gregory KalemkerianAnn Arbor$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.